asx ann:martin rogers is catching an aeroplane, page-43

A reference to "orphan status" appeared on Oct 13, 2008, in "Biotech Daily" concerning the Canadian patent:

"The Canadian Patent Office has granted Prima Biomed subsidiary, Cancer Vac Pty Ltd, apatent covering ovarian cancer immunotherapy product mannan fusion protein.Prima said the patent entitled ‘Antigen carbohydrate compounds and their use inimmunotherapy’ claims priority from November 1994 and expires in November 2014.Prima director Martin Rogers told Biotech Daily that the granting of orphan status gave the company a further seven years of patent coverage."